Introduction
Rabies is a zoonotic disease, and this infection is transmitted to human by the animals which already suffering from it. The animals which are mainly reported as causes of rabies are dogs, raccoons, .
Rabies was a viral disease which cause by the infection of rabies virus.
The rabies virus has bullet morphology (see figure 1 ) and is the type species of the Lyssavirus genus of the Rhabdoviridae family. These viruses are enveloped and have a single stranded RNA genome with negative-sense. The RNA genome of the virus encodes five genes whose order is highly conserved.
These genes code for nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G) and the viral RNA polymerase (L). The G protein was the major protective antigen [2] . All extant rabies viruses appear to have evolved within the last 1500 years, and there's only one serotype [3] . over Europe, Russia, and America [6] .
Despite by sensitization to myelin basic protein [7] . Despite the potentially serious side effects on the central nervous system, the Semple vaccine is still used in humans in Asia and Africa. Fuenzalida and colleagues introduced the first myelin-free inactivated vaccines to rabies virus prepared from neonatal mouse brains [8] . This vaccine type is still widely used in South America and the former Soviet Union.
So the rabies was preventable infectious disease by treated with vaccine, and some kinds of new rabies vaccine were studied successfully.
Duck embryo vaccine
Another vaccine that had less serious reactions was the duck embryo vaccine (DEV) prepared from virus propagated in embryonated duck eggs [9] . However, that contains about 1% of the protein of the DEV therefore reducing the risk of allergic reactions [11, 12] . 
Cell culture vaccine
Cell culture rabies vaccine as a new progress gradually spread. The first tissue culture vaccine was derived from virus grown in primary hamster kidney cells [12, 13] . The primary hamster kidney cell rabies vaccine (PHKCV) was developed in Moscow and is now approved for use and produced in China. This was followed by growth of fixed RABV in a human diploid cell line [14] . The lung-derived cell line WI-38 was used initially, but was WI-38 [15] and the free virus was inactivated by β-propiolactone, and concentrated by ultracentrifugation [16] .
This human diploid cell vaccine (HDCV) induced much better immune responses in animals and humans than
all the other vaccines known at that time [17, 18] . Vaccination with HDCV not only results in higher antibody levels, but also the antibodies appear earlier after vaccination. Using this vaccine, it was for the first time possible to demonstrate that a single injection of the vaccine given several hours after challenge with a virulent virus could protect animals from rabies [19] .
In adsorption to aluminum phosphate [20, 21] .
It is considered to be equal to HDCV with regard to efficacy and safety [22] .
An alternative to HDCV was the use of purified chick embryo cells (PCEC) [23] .
PCECV is prepared from the rabies virus HDCV showed no significant differences between the two vaccines [24, 25] . These vaccines are now used successfully worldwide.
A continuous African green monkey kidney cell line called Vero was used to produce another rabies vaccine [26] . The [27] . PVRV is licensed for use in humans in Europe and in many countries in the developing world.
Animal vaccine
The first vaccine used for mass have also been used to develop oral vaccines for wildlife immunization [28] . [29, 30] .
The easiest way to immunize wildlife animals such as foxes and raccoons is via for rodents, the more attenuated strain SAG2 has been developed and is now used for vaccination of wildlife animals [31] .
Future vaccines of rabies
Despite the undoubted success of current commercial vaccines against rabies there have been numerous attempts to develop alternatives, all taking advantage of the genetic manipulation revolution. Antibodies have been shown to be critical for protection against the spread of RABV [32] . The key target for antibodies is virus glycoprotein.
Glycoprotein is the only surface-exposed protein on the virion particle, and a number of antigenic sites to which neutralizing monoclonal antibodies bind have been identified on this protein [33, 34] . there is strong evidence that this response is antagonized to some extent by the viral phosphoprotein [35, 36] . This subversion may be the reason for the inability of the innate and adaptive immune response to control RABV replication in the central nervous system and leads ultimately to the death of the host. It is therefore encouraging that therapeutic treatment with modified rabies genomes appears to attenuate infection with a more virulent strain [37] , and offers the future possibility that these may form the foundation of a future successful treatment to ameliorate the worst outcomes of RABV infection. 
